News and Trends 14 Mar 2019 Microsoft Aims to Make Cell Therapies Cheaper with Artificial Intelligence Microsoft has launched a collaboration with the UK company Oxford BioMedica to use Microsoft’s artificial intelligence technology to make gene and cell therapy manufacturing easier and cheaper. Genetically programming cells and viruses to make cell and gene therapies is not as simple as programming a computer. Organisms have many layers of complexity and unpredictability, sometimes […] March 14, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Feb 2019 Orchard Achieves Good Survival with Cell Therapy for Rare Immune Deficiency All 20 patients with a rare immunodeficiency disease survived for at least two years after receiving a cell therapy developed by Orchard Therapeutics. The patients had a genetic disease called adenosine deaminase–deficient severe combined immune deficiency (ADA-SCID) — also known as bubble boy syndrome. Caused by a mutation on a vital gene, the disease weakens […] February 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 22 Feb 2019 This Biotech’s Algorithm Accelerates Cell Therapy Development Mogrify is the new kid on the block for cell therapy. Based in Cambridge, UK, it boasts technology that could speed up the development of cell therapies by predicting the best chemical recipe to transform mature adult cells into other cell types. Mission: To use next-generation sequencing and gene expression data to develop more cost-effective […] February 22, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Dec 2018 Looking Back on 2018: Our 10 Most Popular Interviews As 2018 draws to a close and our thoughts are torn between holiday plans and what the new year may bring, we decided to look back and revisit the people and the stories that attracted our readers the most during the year. These were well received the first time around, so we thought you might […] December 24, 2018 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2018 Series B Boosts British Biotech’s Cell Therapy Automation With €22.6M The UK company Synthace has raised €22.6M to develop its software platform to automate and improve the manufacturing process in gene and cell therapy. The round, led by Hong Kong-based investor Horizons Ventures, will help to fund the development of Synthace’s software designed to automate key protocols in the lab. Furthermore, the funding will help […] December 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 5 Dec 2018 How Automation Will Enable the Age of Cell Therapy Scientists in biotech and pharma spend more and more of their valuable time culturing cells manually. Automated cell culture is still not standard in the early research stages, and many believe that needs to change. Philip talked to Ali Afshar, co-founder of Cytera Cellworks to discuss how the main obstacles to bringing automation to cell […] December 5, 2018 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2018 Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease Bone Therapeutics is going to discontinue its cell therapy Phase III trial after finding little hope of success for patients with the bone disease osteonecrosis. If all had gone as planned, the full trial would have monitored 118 patients over 24 months. However, an interim analysis on 44 patients after 12 months found little evidence […] November 7, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2018 Cell Therapy Helps Regenerate Difficult Bone Fractures All patients in a clinical trial run by the Belgian company Bone Therapeutics have seen an improvement in the healing of bone fractures that have had problems healing. Six months after receiving a single dose of the cell therapy developed by Bone Therapeutics, all 21 patients in the Phase I/IIa clinical trial met the primary […] September 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 11 Sep 2018 How To Break Into The Crowded Immuno-Oncology Space The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in this crowded field, many companies struggle to make therapies that not only are effective and safe, but that can also be scaled-up, manufactured and commercialized. Helen Tayton-Martin, Chief Business Officer at the biotech company Adaptimmune, shares her advice on how […] September 11, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2018 Placenta Cell Therapy Improves Mobility in Patients with Peripheral Artery Disease The Israeli biotech Pluristem has Phase II data indicating that its cell therapy made of placenta cells can help patients suffering from peripheral artery disease recover their mobility. The trial, run in the US, Germany, South Korea and Israel, enrolled 172 patients with intermittent claudication, an early stage of peripheral artery disease where the legs […] June 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2018 People with Innate Resistance to HIV Could Provide a Functional HIV Cure In the process of studying HIV-infected patients who naturally don’t need therapy to control the virus, scientists have found what could become a functional cure for HIV infections. A team of researchers from France, Italy, the UK and Australia has identified a molecule that could be transferred to HIV-positive people to help […] June 8, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race Update (23/05/2018): Investors have fully subscribed Celyad’s global offering of shares on NASDAQ and Euronext Paris, making the company raise a total of $54.4M (€46M) to support the development of its CAR-T technology. 18/05/2018 Celyad has raised €40M ($47M) in a global offering, which could help the company keep up with large competitors amidst recent large […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email